stem cells macular degeneration

Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors

Dr.-Masayo-Takahashi-高橋-政代.

Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She won The Niche’s Stem Cell Person of the Year Award in 2014 and a number …

Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors Read More »

1st autologous IPS cell clinical trial for vision loss in the US

Fig.-4a-Schaub-et-al-JCI-2019-

The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a …

1st autologous IPS cell clinical trial for vision loss in the US Read More »

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020

STEM-CELL-PREDICTIONS

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 …

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »

Possible safety concerns from new stem cell, RPE vision loss study report

Figure-1-Mehat-et-al.-AAO-Journal-2018-810x1024-1

With stem cells for vision loss, first we want to be sure a treatment won’t make things worse. Several teams around the globe are rigorously studying stem cell-based approaches to vision loss via regulatory-compliant studies including for macular degeneration with some results cautiously upbeat on safety from early phase analyses, but data from a new study on …

Possible safety concerns from new stem cell, RPE vision loss study report Read More »

15 still unanswered interview questions for stem cells for vision SCOTS trial docs

George-Gibson-SCOTS-patient-screenshot-of-Sun-Sentinel-video-1

There’s a lot going on in Florida with non-FDA approved stem cell offerings even just related to stem cells for vision problems alone, but while US Stem Cell has drawn the most attention related to patient allegations of severe vision loss in Florida after fat stem cell injections in eyes, another group I’ll loosely call the …

15 still unanswered interview questions for stem cells for vision SCOTS trial docs Read More »

Japan conditionally approves new IPS cell-based heart study

Yoshiki-Sawa-IPS-cells-stem-cells-heart-diseease

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work …

Japan conditionally approves new IPS cell-based heart study Read More »

Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives

Takahashi-IPS-transplant

A team of researchers at RIKEN and Kobe City Medical Center reported at a press conference today a serious adverse event in a clinical trial participant receiving an induced pluripotent stem cell (IPS cell)-based therapy for vision loss. According to Japan Times and Yahoo! Japan (in Japanese), the patient in question in the IPS cell …

Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives Read More »

10 for 10 on stem cell day: 10 issues for coming 10 years

Stem-Cell-Symbol-300x298

It’s stem cell day! Or more accurately, it is stem cell awareness day. It’s a good time to think about where our field stands and where we’ll be in 10 years. Below, I’ve outlined 10 for 10: 10 things to ponder about stem cells in a 10-year timeframe. Approved Therapies. How many new stem cell …

10 for 10 on stem cell day: 10 issues for coming 10 years Read More »

Brief update from Bob Lanza on Astellas stem cell program

Lanza-Astellas

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial …

Brief update from Bob Lanza on Astellas stem cell program Read More »